The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

期刊论文
发表日期：

2026年3月30日

查看全文

Maria Agustina Perusini,
Katia Pagnano,
Carolina Pavlovsky,
Daniela Žáčková,
Jiří Mayer,
Beatriz Moiraghi,
Ana Ines Varela,
Michele Bianchini,
Ana Beatriz Pascoal Lopes,
Gislaine Duarte,
Carmino Antonio de Souza,
Ivana Ježíšková,
Anežka Kvetková,
Tomáš Jurček,
Hye Won Lee,
Myung Hee Chang,
Jessie J. F. Medeiros,
Sagi Abelson,
Dennis Dong Hwan Kim

本文未提供摘要，请点击“查看全文”查看完整内容。